1-3 of 3
Karine Egan
Close
Sort by
Journal Articles

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Michael E O'Dwyer, MD, FRCPI, FRCPath, Ronan Swords, MD, MRCPI, FRCPath, Francis Giles, MD FRCPI FRCPath, Mary Frances McMullin, MD, Philipp D. le Coutre, MD, Arnon Nagler, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Karine Egan, Brian Moulton, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD
Journal: Blood
Blood (2011) 118 (21): 3774.
https://doi.org/10.1182/blood.V118.21.3774.3774
Published: 2011
Journal Articles

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Ronan T Swords, MD, MRCPI, FRCPath, Francis J. Giles, MB, MD, FRCPI, FRCPath, Mary Frances McMullin, MD, Philipp le Coutre, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Brian Moulton, Karine Egan, Michael O'Dwyer, MD, FRCPath
Journal: Blood
Blood (2010) 116 (21): 3427.
https://doi.org/10.1182/blood.V116.21.3427.3427
Published: 2010
Journal Articles

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Michael C O'Dwyer, MD, FRCPI, FRCPath, Emma Kent, Michael Parker, BSc, MSc, CStat, CMath, Ronan T. Swords, M.D., Frank Giles, MD, MB, FRCPI, FRCPath, Philipp le Coutre, MD, Swaminathan Padmanabhan, MD, MBBS, Brian Moulton, Ph.D, Mary Frances McMullin, Stephen Langabeer, PhD, Karine Egan, Ph.D, Eibhlin Conneally, MB, MRCP, MRCPath, PhD
Journal: Blood
Blood (2009) 114 (22): 3294.
https://doi.org/10.1182/blood.V114.22.3294.3294
Published: 2009